References
- Sorbe B. Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma. Int J Gynecol Cancer. 2004; 14: 788–93
- Flynn P, Paul J, Cruickshank DJ. Does the interval from primary surgery to chemotherapy influence progression – free survival in ovarian cancer?. Gynecol Oncol. 2002; 86: 354–7
- Paulsen T, Kærn J, Kjærheim K, Haldorsen T, Tropé C. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol. 2006; 102: 447–52
- Gadduci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, et al. Relationship between interval from primary surgery to the start of taxane- plus platinum- based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol. 2005; 23: 751–8
- Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, et al. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol. 2006; 32: 588–91
- Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced stage ovarian cancer?. Gynecol Oncol. 2007; 104: 212–6
- Wright JD, Doan T, McBride R, Jacobson JS, Hershman DL. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008; 98: 1197–203
- Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983; 43: 1488–92
- Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res. 1979; 39: 3861–5
- Schiffenbauer YS, Abramavitch R, Meir G, Nevo N, Holzinger M, Itin A, et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci. 1997; 94: 13203–8
- Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, Saga M, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis. 1998; 16: 751–6